Compare GSK Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA JUBILANT LIFE SCIENCES GSK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 32.6 13.7 237.8% View Chart
P/BV x 13.0 1.7 757.5% View Chart
Dividend Yield % 1.2 0.9 140.2%  

Financials

 GSK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
GSK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs3,595898 400.3%   
Low Rs1,253618 202.9%   
Sales per share (Unadj.) Rs184.7572.0 32.3%  
Earnings per share (Unadj.) Rs26.336.2 72.6%  
Cash flow per share (Unadj.) Rs29.259.5 49.0%  
Dividends per share (Unadj.) Rs20.004.50 444.4%  
Dividend yield (eoy) %0.80.6 138.9%  
Book value per share (Unadj.) Rs126.3301.9 41.8%  
Shares outstanding (eoy) m169.40159.28 106.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.11.3 990.9%   
Avg P/E ratio x92.220.9 440.7%  
P/CF ratio (eoy) x83.112.7 652.8%  
Price / Book Value ratio x19.22.5 764.6%  
Dividend payout %76.112.4 612.4%   
Avg Mkt Cap Rs m410,626120,694 340.2%   
No. of employees `0005.02.4 207.5%   
Total wages/salary Rs m5,37219,260 27.9%   
Avg. sales/employee Rs Th6,306.738,120.6 16.5%   
Avg. wages/employee Rs Th1,083.18,058.4 13.4%   
Avg. net profit/employee Rs Th898.02,414.3 37.2%   
INCOME DATA
Net Sales Rs m31,28191,108 34.3%  
Other income Rs m1,023357 286.3%   
Total revenues Rs m32,30491,466 35.3%   
Gross profit Rs m6,00917,390 34.6%  
Depreciation Rs m4863,709 13.1%   
Interest Rs m62,198 0.3%   
Profit before tax Rs m6,54011,840 55.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m287-2,802 -10.2%   
Tax Rs m2,3733,268 72.6%   
Profit after tax Rs m4,4545,770 77.2%  
Gross profit margin %19.219.1 100.6%  
Effective tax rate %36.327.6 131.5%   
Net profit margin %14.26.3 224.8%  
BALANCE SHEET DATA
Current assets Rs m20,06145,848 43.8%   
Current liabilities Rs m14,54320,897 69.6%   
Net working cap to sales %17.627.4 64.4%  
Current ratio x1.42.2 62.9%  
Inventory Days Days5757 100.0%  
Debtors Days Days1451 27.6%  
Net fixed assets Rs m14,34365,498 21.9%   
Share capital Rs m1,694159 1,063.4%   
"Free" reserves Rs m19,70447,930 41.1%   
Net worth Rs m21,39848,089 44.5%   
Long term debt Rs m242,429 0.0%   
Total assets Rs m39,113114,685 34.1%  
Interest coverage x1,091.06.4 17,082.5%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.80.8 100.7%   
Return on assets %11.46.9 164.1%  
Return on equity %20.812.0 173.5%  
Return on capital %31.912.4 257.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53412,422 4.3%   
Fx outflow Rs m7,09117,227 41.2%   
Net fx Rs m-6,557-4,805 136.5%   
CASH FLOW
From Operations Rs m3,99411,215 35.6%  
From Investments Rs m-1,433-10,118 14.2%  
From Financial Activity Rs m-3,5846,574 -54.5%  
Net Cashflow Rs m-1,0237,612 -13.4%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 50.7 3.5 1,448.6%  
Indian inst/Mut Fund % 10.2 8.7 117.2%  
FIIs % 23.8 21.2 112.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.1 73.0%  
Shareholders   102,036 23,815 428.5%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   IPCA LABS  SANOFI INDIA  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 22, 2019 03:17 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS